X‑Linked Recessive G6PD Deficiency
Overview
Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic disorder of red blood cells,
affecting an estimated 400 million people worldwide.[1]
It is inherited in an X‑linked recessive pattern, meaning the gene responsible is located on the X
chromosome. Because males have only one X chromosome, they are usually fully affected when they inherit a
mutated copy. Females have two X chromosomes, so they are typically carriers; however, due to
The condition is most prevalent in regions where malaria is endemic (sub‑Saharan Africa, the Mediterranean, the Middle East, and parts of Asia) because the reduced enzyme activity offers a survival advantage against the malaria parasite.[2] In the United States, the overall prevalence is about 1–2 % of the population, but rates are higher among individuals of African, Mediterranean, or Southeast Asian descent.
Symptoms
Symptoms arise when red blood cells (RBCs) are exposed to oxidative stress that the deficient enzyme cannot neutralize. The clinical picture can range from completely asymptomatic to life‑threatening hemolysis.
Acute Hemolytic Episodes
- Sudden onset of fatigue, weakness, or shortness of breath – due to rapid loss of RBCs.
- Dark urine (cola‑colored) – hemoglobin released from lysed RBCs filters into the urine.
- Jaundice – yellowing of the skin and sclera from elevated bilirubin.
- Back or abdominal pain – from splenic congestion.
- Palpitations or rapid heartbeat (tachycardia) – compensatory response to anemia.
Chronic or Sub‑acute Findings
- Chronic mild anemia – persistent low hemoglobin without obvious triggers.
- Splenomegaly – enlarged spleen from ongoing removal of damaged RBCs.
- Gallstones – bilirubin stones can form after repeated hemolysis.
Neonatal Presentation
- Newborns may develop jaundice within the first 24‑48 hours, sometimes requiring phototherapy.
- Severe cases can progress to kernicterus, a form of brain injury, if untreated.
Triggers that Precipitate Symptoms
- Infection (especially viral respiratory infections).
- Medications: sulfa drugs, certain antimalarials (primaquine, chloroquine), quinine, dapsone, nitrofurantoin, some antibiotics.
- Foods: fava beans (hence “favism”), certain legumes.
- Chemical exposure: naphthalene (mothballs), certain industrial oxidants.
Causes and Risk Factors
Genetic Basis
The G6PD gene encodes the G6PD enzyme, a key player in the pentose‑phosphate pathway that generates nicotinamide adenine dinucleotide phosphate (NADPH). NADPH protects RBCs from oxidative damage. Over 400 different G6PD gene variants have been identified; they are classified by the World Health Organization (WHO) into five classes based on residual enzyme activity and clinical severity.[3] Class I–II variants typically cause chronic hemolysis, while Class III variants usually present only with episodic hemolysis.
Who Is at Higher Risk?
- Sex: Males (XY) are at highest risk; females (XX) are carriers and may be symptomatic if they are homozygous or have skewed X‑inactivation.
- Ethnicity: African, Mediterranean (Greek, Italian, Turkish), Middle Eastern, South Asian, and Southeast Asian ancestry.
- Family history: A brother, father, or maternal uncle with known G6PD deficiency raises the probability.
- Geographic exposure: Living in or traveling to malaria‑endemic regions where prophylactic antimalarial drugs are used.
Diagnosis
Diagnosis combines a clinical suspicion (history of triggers and hemolysis) with laboratory confirmation.
Screening Tests
- Quantitative G6PD enzyme assay – measures enzyme activity in red blood cells. Results are expressed as U/g Hb; <10 % of normal is considered deficient.
- Fluorescent spot test – a rapid bedside screen using NADPH fluorescence.
- DNA genetic testing – identifies specific mutations; useful for carrier testing in women or prenatal diagnosis.
Additional Laboratory Findings During an Acute Episode
- Complete blood count (CBC): low hemoglobin, elevated reticulocyte count.
- Lactate dehydrogenase (LDH) and indirect bilirubin: markedly increased.
- Haptoglobin: decreased (consumed during hemolysis).
- Urinalysis: positive for hemoglobin, no red cells (indicating hemoglobinuria).
When to Test
Screening is recommended for newborns in high‑prevalence regions, before prescribing known oxidant drugs, and for individuals with a personal or family history of unexplained hemolysis. Because enzyme activity can appear falsely normal during a recent transfusion, testing should be repeated at least 3 months after the event.
Treatment Options
There is no cure; management focuses on preventing oxidative stress and treating acute hemolysis.
Acute Management
- Remove the trigger – stop offending medication, avoid fava beans, treat underlying infection.
- Supportive care – intravenous fluids to maintain renal perfusion, analgesics for pain.
- Transfusion of packed red blood cells – indicated for severe anemia (Hb < 7 g/dL) or symptomatic cardiovascular compromise.
- Folate supplementation – 1 mg daily during hemolysis to support RBC regeneration.
Long‑Term Strategies
- Education list of contraindicated substances (see “Prevention” section).
- Vaccination – especially against influenza and pneumococcus, which can precipitate hemolysis.
- Regular monitoring – annual CBC and bilirubin for patients with chronic hemolysis.
Emerging Therapies
Research is exploring enzyme replacement and gene‑editing approaches (CRISPR‑Cas9) but they remain experimental and unavailable in routine clinical practice as of 2024.[4]
Living with X‑Linked Recessive G6PD Deficiency
Empowering patients with knowledge and practical habits reduces the frequency of crises.
Daily Management Tips
- Maintain a written “safe‑list” of foods, drugs, and chemicals to avoid; keep it on a wallet card and share with healthcare providers.
- Read medication labels carefully; ask pharmacists about oxidant potential.
- Stay hydrated – adequate fluid intake helps the kidneys clear free hemoglobin.
- Balanced diet – include folate‑rich foods (leafy greens, beans, fortified cereals) to aid RBC production.
- Monitor for signs of hemolysis (dark urine, sudden fatigue) and seek prompt medical review.
- Travel preparation – obtain a copy of the safe‑list, carry a medical alert bracelet, and discuss malaria prophylaxis with a travel clinic.
Family Planning
Carrier testing for female relatives is recommended. Genetic counseling helps couples understand recurrence risk: a carrier mother and an affected father have a 50 % chance of having affected sons and a 50 % chance of carrier daughters.
Prevention
Because the genetic defect cannot be eliminated, prevention centers on avoiding triggers.
Medication Safety
| Class | Common Examples | Reason to Avoid |
|---|---|---|
| Sulfonamides | Trimethoprim‑sulfamethoxazole, sulfadiazine | Oxidant stress |
| Antimalarials | Primaquine, chloroquine, quinine | Highly oxidative |
| Antibiotics | Dapsone, nitrofurantoin, fluoroquinolones | Can precipitate hemolysis |
| Analgesics | Acetaminophen (large doses), aspirin (high dose) | Rare but reported |
Dietary Guidance
- Avoid fava beans (broad beans) and foods made from them (e.g., certain flours).
- Limit other legumes only if a known personal reaction occurs.
- Consume moderate amounts of antioxidants (vitamin C, E) – evidence is limited but generally safe.
Environmental Precautions
- Do not use mothballs (naphthalene) in clothes or storage areas.
- Avoid exposure to industrial chemicals known to cause oxidative stress unless protective equipment is used.
Complications
If episodes are frequent or severe, several long‑term complications may develop:
- Chronic anemia – leading to fatigue, reduced exercise tolerance, and, in children, growth retardation.
- Gallstone disease – bilirubin stones from repeated hemolysis.
- Acute kidney injury – hemoglobinuria can cause tubular obstruction.
- Splenic infarction or rupture – rare but possible after massive hemolysis.
- Hyperbilirubinemia in neonates – risk of kernicterus if untreated promptly.
When to Seek Emergency Care
- Sudden, severe fatigue or dizziness accompanied by rapid heartbeat.
- Dark (cola‑colored) urine or a sudden decrease in urine output.
- Rapidly worsening jaundice (yellowing of skin or eyes).
- Chest pain, shortness of breath at rest, or fainting.
- Severe abdominal or back pain that does not improve.
- Signs of an allergic reaction after taking a new medication (swelling, hives, trouble breathing).
Prompt treatment can prevent kidney damage and reduce the need for transfusion.
References
- Mayo Clinic. “G6PD deficiency.” Updated 2023. https://www.mayoclinic.org
- World Health Organization. “Global prevalence of G6PD deficiency: a systematic review.” 2022.
- Cleveland Clinic. “G6PD Deficiency (Glucose‑6‑Phosphate Dehydrogenase).” 2023. https://my.clevelandclinic.org
- NIH National Heart, Lung, and Blood Institute. “Gene Therapy for G6PD Deficiency – Clinical Trials.” 2024.
- CDC. “Travelers’ Health: Malaria Chemoprophylaxis and G6PD Deficiency.” 2023.